Search research articles
Contact Us
Filters
Showing results (551-560 of 605) with videos related to
Page
of 61
Sort By:
Radiation Protection Dosimetry
|
October 28, 2015
SECOND LATIN AMERICAN INTERCOMPARISON ON INTERNAL DOSE ASSESSMENT
A Rojo, N Puerta, S Gossio, et al.
The New England Journal of Medicine
|
September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Cancer Treatment and Research Communications
|
April 15, 2025
Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1
M Sereno, A Collazo-Lorduy, Y Garitaonaindia, et al.
International Journal of Oral and Maxillofacial Surgery
|
December 13, 2024
Between unity and disparity: current treatment protocols for common orofacial clefts in European expert centres
V L van Roey, A B Mink van der Molen, I M J Mathijssen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Clinical and Translational Medicine
|
December 19, 2022
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism
Mayra A Gonzalez, Idaly M Olivas, Alfonso E Bencomo-Alvarez, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Neurology
|
April 13, 2005
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
R H S R Roxburgh, S R Seaman, T Masterman, et al.
Cancer Medicine
|
September 10, 2025
Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results
J Rubio-Briones, A Borque-Fernando, L M Esteban Escaño, et al.
Page
of 61
Search research articles
Search
Showing results (551-560 of 605) with videos related to
Sort By:
Page
of 61
Radiation Protection Dosimetry
|
October 28, 2015
SECOND LATIN AMERICAN INTERCOMPARISON ON INTERNAL DOSE ASSESSMENT
A Rojo, N Puerta, S Gossio, et al.
The New England Journal of Medicine
|
September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Cancer Treatment and Research Communications
|
April 15, 2025
Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1
M Sereno, A Collazo-Lorduy, Y Garitaonaindia, et al.
International Journal of Oral and Maxillofacial Surgery
|
December 13, 2024
Between unity and disparity: current treatment protocols for common orofacial clefts in European expert centres
V L van Roey, A B Mink van der Molen, I M J Mathijssen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Clinical and Translational Medicine
|
December 19, 2022
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism
Mayra A Gonzalez, Idaly M Olivas, Alfonso E Bencomo-Alvarez, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Neurology
|
April 13, 2005
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
R H S R Roxburgh, S R Seaman, T Masterman, et al.
Cancer Medicine
|
September 10, 2025
Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results
J Rubio-Briones, A Borque-Fernando, L M Esteban Escaño, et al.
Page
of 61